Compositions and methods for nanoparticle lyophile forms
Compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.
1. A process for making a nucleic acid drug product, the process comprising:
synthesizing lipid nanoparticles, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents;
providing an aqueous suspension of the lipid nanoparticles in a pharmaceutically acceptable solution;
adding a dextrin compound to the solution containing the lipid nanoparticles;
adding a saccharide sugar compound to the solution containing the lipid nanoparticles;
lyophilizing the solution containing the lipid nanoparticles, thereby forming a solid lyophile; and
reconstituting the lyophile in a pharmaceutically acceptable carrier, thereby forming a nucleic acid drug product,
wherein the total amount of the dextrin and saccharide sugar compounds is from 10% to 12% (w/v) of the solution containing the lipid nanoparticles, and
wherein the dextrin compound is from 40% to 45% (w/v) of the total amount of the dextrin and saccharide sugar compounds,
wherein the lipid nanoparticles comprise a compound selected from the group consisting of compound A6, compound A9, compound AA, compound AB, compound C2, compound F5, compound F7, compound C24, and hydroxyethyl disulfide cholesterol (HEDC),
wherein the compound A6 is:
the compound A9 is:
the compound AA is:
the compound AB is:
the compound C2 is:
the compound F5 is:
the compound F7 is:
and
the compound C24 is:
2. The process of claim 1 , wherein upon reconstitution, the change of average size of the nanoparticles is within 10% of their size when synthesized.
3. The process of claim 1 , further comprising storing the lyophile before reconstitution,
wherein upon storage and reconstitution of the lyophile, the change of average size of the nanoparticles is within 10% of their size when synthesized, and
wherein the lyophile is stored at 5 or −20° C. for at least one month.
4. The process of claim 1 , wherein the nanoparticles have an average diameter of from 45 nm to 110 nm.
5. The process of claim 1 , wherein the concentration of the nucleic acid active agents is from 1 mg/mL to 10 mg/mL.
6. The process of claim 1 , wherein the one or more nucleic acid active agents are RNAi molecules capable of mediating RNA interference.
7. The process of claim 1 , wherein the pharmaceutically acceptable solution is a HEPES buffer, a phosphate buffer, a citrate buffer, or a buffer containing Tris(hydroxymethyl)aminomethane.
8. The process of claim 1 , wherein the dextrin compound is a cyclodextrin.
9. The process of claim 8 , wherein the cyclodextrin compound has one or more of the 2, 3 and 6 hydroxyl positions substituted with sulfoalkyl, benzenesulfoalkyl, acetoalkyl, hydroxyalkyl, hydroxyalkyl succinate, hydroxyalkyl malonate, hydroxyalkyl glutarate, hydroxyalkyl adipate, hydroxyalkyl, hydroxyalkyl maleate, hydroxyalkyl oxalate, hydroxyalkyl fumarate, hydroxyalkyl citrate, hydroxyalkyl tartrate, hydroxyalkyl malate, or hydroxyalkyl citraconate groups.
10. The process of claim 8 , wherein the cyclodextrin compound is (2-hydroxypropyl)-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin succinate, (2-hydroxypropyl)-γ-cyclodextrin, or 2-hydroxypropyl-γ-cyclodextrin succinate.
11. The process of claim 8 , wherein the cyclodextrin compound is sulfobutyl ether β-cyclodextrin or sulfobutyl ether γ-cyclodextrin.
12. The process of claim 8 , wherein the cyclodextrin compound is methyl-β-cyclodextrin or methyl-γ-cyclodextrin.
13. The process of claim 8 , wherein the cyclodextrin compound includes an adsorbate compound.
14. The process of claim 1 , wherein the saccharide sugar compound is a monosaccharide or disaccharide sugar compound.
15. The process of claim 1 , wherein the pharmaceutically acceptable carrier is sterile water, water for injection, sterile normal saline, bacteriostatic water for injection, or a nebulizer solution.
16. The process of claim 1 , wherein the pharmaceutically acceptable carrier is a pharmaceutically acceptable solution.
17. The process of claim 1 , wherein the reconstituted nucleic acid drug product has less 0.001% (w/v) of aggregate particles with a size greater than 0.2 μm.
18. The process of claim 1 , wherein the nucleic acid drug product is reconstituted in a time period of 3 to 30 seconds.
19. The process of claim 1 , wherein the nucleic acid drug product is reconstituted after a storage time period of six months and retains 80% activity of the nucleic acid agents.